IN10018 in Combination With Dalpiciclib for Progressive Meningiomas
A legfontosabb adatok
- Ki végzi
- Capital Medical University
- Hol
- Kína2 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 24 fő, tervezett
- Kezdés
- 2026. aug. 31.
- Várható befejezés
- 2029. aug.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Ifebemtinib
- Dalpiciclib
- A regiszteradat frissítve
- 2026. október 21.
Ki vehet részt
The trial is looking for adults with a meningioma that keeps growing or came back after treatment. The meningioma is a tumor of the membranes around the brain. People take IN10018 with dalpiciclib by mouth.
- Életkor
- 18 years or older
- Nem
- Men and women
- A betegség stádiuma
- Meningioma confirmed by tissue test. It must be WHO Grade 2 or Grade 3. Or it is WHO Grade 1 that came back after surgery or radiotherapy and is clearly growing. At least one tumor must be measurable on scans.
- Korábbi kezelés
- No standard treatment is available, or standard treatment such as surgery, radiotherapy or other drug therapy has failed. Radiotherapy must have ended at least 24 weeks ago. People cannot join if they had a focal adhesion kinase inhibitor or a CDK4/6 inhibitor, including dalpiciclib.
- A részvétel fő kizáró okai
- Major surgery or major injury within 28 days before the first dose, or a biopsy within 14 days
- Serious heart problems within 6 months, such as heart pumping strength (ejection fraction) below 50%
- Unable to take pills by mouth, or serious bowel or stomach disease
- Known HIV infection, or known active hepatitis B or hepatitis C
- Pregnant or breastfeeding
A regiszter összes feltétele (24)A regiszter feltételeinek elrejtése
Ki vehet részt
- Participants must be able to understand and willing to sign a written informed consent form and agree to comply with all study requirements. Written informed consent must be obtained before any study-related examination or procedure is performed
- Aged 18 years or older, male or female
- Histologically confirmed meningioma meeting at least one of the following conditions:
- World Health Organization (WHO) Grade 2 or Grade 3 meningioma; or
- WHO Grade 1 meningioma that has recurred after surgery or radiotherapy and demonstrates clear radiographic or clinical progression, as determined by the investigator; No available standard treatment option, or failure of standard treatment, including surgery, radiotherapy, or other systemic therapy; At least 24 weeks must have elapsed since completion of radiotherapy, including external beam radiation therapy, brachytherapy, or radiosurgery such as Gamma Knife or CyberKnife; At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), as confirmed by the investigator; Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Estimated life expectancy of at least 3 months, as determined by the investigator; Adverse effects caused by previous treatments must have recovered to Grade 1 or lower according to the Common Terminology Criteria for Adverse Events (CTCAE), except for alopecia and fatigue; The dose of corticosteroids or other hormonal treatment must have been stable for at least 4 days before enrollment; Adequate hematologic and organ function, based on laboratory tests performed within 7 days before the first dose, as follows:; Hematologic function:
- Hemoglobin of at least 100 g/L, without dependence on red blood cell transfusion or erythropoietin
- Platelet count of at least 100 × 10\^9/L, without dependence on platelet transfusion
- Absolute neutrophil count of at least 1.5 × 10\^9/L, without the use of colony-stimulating factors; Hepatic function:
- Total bilirubin no greater than the upper limit of normal
- Alanine aminotransferase and aspartate aminotransferase no greater than 2.5 times the upper limit of normal; Renal function:
- Serum creatinine no greater than 1.5 times the upper limit of normal
- Either creatinine clearance calculated using the Cockcroft-Gault formula of at least 60 mL/min or estimated glomerular filtration rate calculated using the Modification of Diet in Renal Disease formula of at least 60 mL/min/1.73 m²; Urinary protein and coagulation function:
- Urine protein negative or trace. Participants with urine protein of 1+ must have a morning spot urine protein-to-creatinine ratio of less than 0.5 or 24-hour urinary protein of less than 0.5 g/24 hours
- International normalized ratio no greater than 1.5 and activated partial thromboplastin time no greater than 1.5 times the upper limit of normal; Female participants must not be pregnant or breastfeeding and must meet one of the following conditions:
- Not be a woman of childbearing potential; or
- If a woman of childbearing potential, agree to follow the protocol-specified contraceptive requirements during study treatment and for 3 months after the last dose
Ki nem vehet részt
- Major surgery or major trauma within 28 days before the first dose, or diagnostic biopsy within 14 days before the first dose
- Receipt of systemic anticancer treatment, including an investigational drug, within the protocol-specified washout period, including chemotherapy or targeted therapy within 14 days or 5 half-lives before the first dose, whichever is shorter, or immunotherapy within 28 days before the first dose
- Previous treatment with a focal adhesion kinase inhibitor or a cyclin-dependent kinase 4/6 inhibitor, including dalpiciclib
- A serious cardiovascular event or clinically significant cardiovascular condition within 6 months before initiation of study treatment, including but not limited to:
- New York Heart Association functional class 2 or higher
- Left ventricular ejection fraction below 50%
- Corrected QT interval greater than 480 milliseconds
- History of serious arrhythmia or cardiomyopathy. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage. Participants with small-volume effusions detectable only by imaging may be considered eligible; Malabsorption syndrome or inability to take oral medication. Serious gastrointestinal disease, including uncontrolled inflammatory gastrointestinal disease, active Crohn disease, active ulcerative colitis, or uncontrolled gastrointestinal bleeding; Active infection that is not adequately controlled by systemic treatment. Known human immunodeficiency virus infection. Human immunodeficiency virus testing is not required during screening unless mandated by local regulations or institutional policy; Known active hepatitis B virus or hepatitis C virus infection. Hepatitis B virus and hepatitis C virus testing is not required during screening unless mandated by local regulations or institutional policy; Any medical history, treatment, laboratory abnormality, or other condition that, in the investigator's judgment, could confound interpretation of the study results, interfere with participant compliance, or compromise the participant's safety or interests; Known psychiatric illness or substance abuse that could interfere with compliance with study requirements; Known hypersensitivity to IN10018, dalpiciclib, or any component of either study drug; Systemic treatment with a strong inhibitor or inducer of CYP3A4, CYP2D6, or P-glycoprotein within 14 days before the first dose, or anticipated need for such treatment during the study treatment period
Alkalmassági kérdőív
Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.
- Életkor
- Meningioma vagy CDK4/6 inhibitor
Ez a vizsgálat jelenleg itt érhető el: Kína.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This open-label Phase Ib study will evaluate the safety, tolerability, and preliminary effectiveness of IN10018 in combination with dalpiciclib in adults with progressive meningiomas. Progressive meningiomas are tumors arising from the membranes surrounding the brain that have continued to grow or have returned after previous treatment.
A teljes eredeti leírásKevesebb
Participants will receive both study drugs by mouth in 28-day treatment cycles. IN10018 and dalpiciclib will each be taken once daily for 21 days, followed by 7 days off in each 28-day cycle. Treatment may continue until the tumor progresses, unacceptable side effects occur, or another reason for stopping treatment applies.
The study includes a dose-confirmation phase and a dose-expansion phase. The main goals are to evaluate side effects and determine a recommended dose of the combination for further study. Researchers will also assess whether the treatment can shrink tumors or delay tumor growth, measure how the drugs are processed in the body, and explore tumor and blood biomarkers that may be associated with treatment response.
A vizsgálat csoportja
- IN10018 Plus DalpiciclibA vizsgált kezelés
Participants will receive oral IN10018 in combination with oral dalpiciclib in 28-day treatment cycles. IN10018 will be administered once daily at 100 mg on Days 1 through 21 of each cycle, followed by 7 days off treatment, with a permitted reduced dose of 50 mg. Dalpiciclib will be administered once daily at 125 mg on Days 1 through 21 of each cycle, followed by 7 days off treatment, with a permitted reduced dose of 100 mg. A modified 3+3 design will be used during dose confirmation to determine the recommended dose. Participants enrolled in the dose-expansion phase will receive the combination at the recommended dose. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or another protocol-defined discontinuation criterion.
Kezelés: Ifebemtinib és Dalpiciclib
Következő lépések
Az orvosodnak
Kérdőlap az orvosnak
PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 2 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.
PDF, US Letter, 1–2 oldal. A4 méretben
A vizsgálati csapatnak
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Open-Label Phase Ib Clinical Study Evaluating the Safety, Tolerability, and Efficacy of IN10018 in Combination With Dalpiciclib in Participants With Progressive Meningiomas
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07652762: ki vehet részt
- A regiszteradat frissítve
- 2026. október 21.